Skip to main content
Top
Published in: Breast Cancer Research 1/2000

01-12-2001 | Paper Report

An in vitrobreast cell immortalisation assay

Published in: Breast Cancer Research | Issue 1/2000

Login to get access

Excerpt

In most normal human cells there is a progressive shortening of chromosomal telomeres with successive cell divisions, leading ultimately to cell senescence. Cellular immortalisation is thought to occur by the reactivation of a telomerase which prevents telomere shortening and consequent growth arrest. As telomerase activity has been detected in 90% of cancers tested, it may be a good target in cancer treatment. Early-onset breast cancer is prevalent amongst patients with Li-Fraumeni syndrome (LFS). In previous studies, the authors demonstrated that normal breast epithelial cells from women with LFS immortalise spontaneously in culture. Normal breast epithelial cells were used in an in vitro assay to investigate the effects of chemopreventive and antitelomerase agents on telomerase activity and the immortalisation process. …
Literature
1.
go back to reference Herbert B-S, Wright AC, Passons CM, Wright WE, Ali IU, Kopelovich L, Shay JW: Effects of chemopreventive and antitelomerase agents on the spontaneous immortalization of breast epithelial cells. J Natl Cancer Inst . 2001, 93: 39-45.CrossRefPubMed Herbert B-S, Wright AC, Passons CM, Wright WE, Ali IU, Kopelovich L, Shay JW: Effects of chemopreventive and antitelomerase agents on the spontaneous immortalization of breast epithelial cells. J Natl Cancer Inst . 2001, 93: 39-45.CrossRefPubMed
Metadata
Title
An in vitrobreast cell immortalisation assay
Publication date
01-12-2001
Published in
Breast Cancer Research / Issue 1/2000
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr-2001-68453

Other articles of this Issue 1/2000

Breast Cancer Research 1/2000 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine